Abstract YO30
Case summary
BACKGROUND
Patients with cancer are at a higher risk for COVID-19 infection with consequently worse outcomes. This case series aim is to understand the demographic, clinical profile and outcomes of cancer patients with COVID-19 in a tertiary hospital in Davao City to provide for better quality of care for this subset of patients.
METHODS
Cancer patients with COVID-19 infection admitted at a tertiary hospital in Davao City were identified. Data were obtained through chart review. Information included were from patients diagnosed from March 2020 to September 22, 2020.
RESULTS
Fourteen cancer patients were diagnosed with COVID-19, with a median age of 45 years (range 19-61 years), and 10 (71%) are females. Three (21%) patients have hypertension and diabetes. Tumors mostly were from the CNS (21%) while breast, GUT, head and neck, lymphoma each represent 14% of the total cases. 64% of patients have stage 4 disease, 3(21%) patients had stage 3. Four (29%) patients had chemotherapy within the last 3 months of admission. Dyspnea (36%), cough (29%) and fatigue (21%) are the most common symptoms. Chest radiograph finding of bilateral infiltrates was seen in 7 (50%) patients. CRP and serum ferritin were the most common laboratory abnormalities seen in 11 (79%) patients. Nine (64%) patients received supplemental oxygen and 4 (29%) needed ventilator assistance. Steroids was given in 3 (21%) patients and 11(79%) received antibiotics. Complications of acute respiratory failure was seen in 5(36%) patients and 2 (14%) had septic shock. There were 6 (43%) COVID-19 related deaths and 7 (50%) patients were discharged. The median length of hospital stay is at 13 days.
CONCLUSIONS
Cancer patients have increased risk of contracting COVID-19 infection and are more likely to have worse COVID-19 disease and outcomes.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06